2018 Long Term Incentive Plan and Grant of Options to PDMRs

Venture Life Group PLC
(“Venture Life” or the “Company”)

Venture Life (AIM: VLG), the international consumer self-care group focused on developing, manufacturing and commercialising products for the self-care market, announces that it has granted further nominal-cost share options ("Options") over ordinary shares of 0.3p each in Venture Life ("Shares") under the Venture Life Group plc 2016 Long Term Incentive Plan ("LTIP").

On 23 March 2018 (the "Date of Grant"), Venture Life granted Options over a total of 1,358,806 Shares to its four Executive Directors. Vesting of the Options is subject to continued employment and the Company meeting objective performance conditions, namely the Company's Earnings Per Share ("EPS") performance and relative Total Shareholder Return (share price performance plus dividends added back, "TSR"). Half of the Options granted are subject to EPS performance and half subject to TSR performance.

This tranche of 1,358,806 Options will vest on 23 March 2021, subject to meeting the performance conditions set for the Company's EPS over the three financial years ending 31 December 2020 and TSR for the three years commencing 23 March 2018. The Options are exercisable at a price of 0.3p per Share.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

The lapsed options relate to options issued in 2015 that have now lapsed as the performance conditions attached to them were not met.

Name of authorised official of issuer responsible for making notification.

Peter Shepherd

Company Secretary to Venture Life Group plc


Venture Life Group PLC +44 (0) 1344 742870
Jerry Randall, Chief Executive Officer
James Hunter, Chief Financial Officer

Panmure Gordon (UK) Limited (Nominated Adviser and Joint Broker) +44 (0) 20 7886 2500
Freddy Crossley/Peter Steel/Duncan Monteith (Corporate Finance)
Tom Salvesen (Corporate Broking)

Turner Pope Investments (TPI) Ltd (Joint Broker) +44 (0) 20 3621 4120
James Pope/Ben Turner

Walbrook PR venturelife@walbrookpr.com or +44 (0) 20 7933 8780
Paul McManus/Anna Dunphy +44 (0) 7980 541 893 / +44 (0) 7876 741 001

About Venture Life (www.venture-life.com)
Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the ageing population. The Group’s product portfolio includes some key products such as the UltraDEX oral care products range, food supplements for lowering cholesterol and maintaining brain function, medical devices for women’s intimate healthcare and haemorrhoids and dermo-cosmetics for addressing the signs of ageing.
The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies supplied by the Group’s international distribution partners.
Through its Development & Manufacturing business in Italy, Biokosmes, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.